Track Oxford Biomedica plc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Oxford Biomedica plc OXOA.F · Stock Open Oxford Biomedica plc in new tab

6.00 EUR
Add to portfolio
EPS
-0.31
P/B
6.79
ROE
-40.37
Beta
1.10
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
EPS-0.31
Book Value0.88
Price to Book6.79
Debt/Equity162.16
% Insiders20.547%
Growth
Revenue Growth0.23%

DCF Valuation

Tweak assumptions to recompute fair value for Oxford Biomedica plc (OXOA.F)
Currency: EUR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Oxford Biomedica plc Logo Oxford Biomedica plc Analysis (OXOA.F)

United Kingdom Health Care Official Website Stock

Is Oxford Biomedica plc a good investment? Oxford Biomedica plc (OXOA.F) is currently trading at 6.00 EUR.

Investor FAQ

Does Oxford Biomedica plc pay a dividend?

No, it does not currently pay a dividend.

What asset class is Oxford Biomedica plc?

Oxford Biomedica plc is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

Company Profile

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary ‘plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Exchange Ticker
FRA (Germany) OXOA.F
PNK (United States) OXBDF
STU (Germany) OXOA.SG
LSE (United Kingdom) OXB.L
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion